Biogen Idec's CEO Discusses Q4 2011 Results - Earnings Call Transcript Seeking Alpha SELECT, the first of 2 registrational trials for Daclizumab, showed impressive clinical results in 2011 and supported the continuation of the second registrational study, DECIDE. We also completed enrollment for ADVANCE, our Phase III trial, ... |
